[Recombinant Oka varicella vaccine as a live hepatitis B virus vaccine].
Recombinant Oka varicella-hepatitis B virus (HBV) vaccine was constructed by inserting the HBV surface antigen (HBsAg) gene coding partial PreS2 and whole S regions into the viral thymidine kinase gene. HBsAg was expressed in the cytoplasm of infected cells. Intracellular HBsAg (26K and 30K) was N- and O-glycosylated, sialylated, and secreted into the supernatant as 30K and 35K HBsAg particles. Recombinant virus induced antibody response to both varicella-zoster virus and HBsAg in guinea pigs and the level of antibody titers to HBsAg was comparable in guinea pigs immunized with a live varicella-HBV vaccine or commercial HBs subunit vaccine. Altogether, this recombinant virus may be a good candidate for the live varicella-HBV vaccine.